AzTrials
AzTrials

Major Depressive DisorderNCT07221929

Exercise-priming of CBT for Depression: the CBT+ Trial

A study testing Rest and Aerobic Activity in people with Major Depressive Disorder, run by University of Wisconsin, Madison at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study investigates the effects of intentionally sequencing aerobic exercise immediately prior to cognitive behavioral therapy (CBT) to determine its effects on mechanisms of CBT (i.e., working alliance, behavioral activation). Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Major Depressive Disorder
What is being tested?
Rest and Aerobic Activity
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
1 siteUnited States
Study dates
5 Jan 2026to Dec 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • a diagnosis of DSM-5 (Diagnostic and Statistical Manual of Mental Disorders-5) MDD, confirmed via Structured Clinical Interview for DSM-5 (SCID)
  • current depressive symptoms of at least mild severity defined by a Hamilton Rating Scale of Depression (using the GRID-HAMD) score greater than or equal to 8
  • EITHER not currently take any mental health medications or use other mental health treatment (e.g., behavioral, psychological) OR be on a stable mental health medication and/or treatment regimen for the past 8 weeks, and encouraged to maintain that regimen for the duration of the 8 week intervention period
  • willing and safe to perform exercise based on responses on the Physical Activity Readiness Questionnaire (rules out contraindications to exercise)
  • reported being CBT-naïve (as defined by never undergoing structured CBT).

Who cannot join

  • reporting being currently pregnant, nursing, or planning to become pregnant during the study
  • being diagnosed with current Substance Use Disorder, via the SCID
  • being diagnosed with lifetime or current Psychosis, Mania, or Bipolar Disorder, via the SCID
  • having class III+ obesity (BMI greater than or equal to 40)
  • active suicidal ideation with specific plan and intent ('5' score on Suicidal Ideation from Columbia Suicide Severity Rating Scale [C-SSRS])
  • exhibiting behavioral disturbance (e.g., aggression, mild-moderate cognitive impairment) or relationships with the study team members (e.g., therapists) that would significantly interfere with study participation, as assessed by research personnel.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Madeleine Connolly, PhD contact

(608) 890-0154

mconnolly5@wisc.edu

Jeni Lansing, PhD contact

United States1 site, 1 recruiting
  • University of Wisconsin

    Madison, Wisconsin, 53792

    Recruiting

Other trials in United States

About this study

This study investigates the effects of intentionally sequencing aerobic exercise immediately prior to cognitive behavioral therapy (CBT) to determine its effects on mechanisms of CBT (i.e., working alliance, behavioral activation). To assess the utility of this treatment augmentation, investigators will conduct a randomized controlled trial involving 100 adults with Major Depressive Disorder who will watch a nature documentary while either resting quietly ( 'CalmCBT') or exercising at a moderate intensity ('ActiveCBT') immediately prior to 8 weekly sessions of CBT.

Read the detailed description

The overall goals of this project are to examine the efficacy of exercise priming (i.e., intentional sequencing of aerobic exercise immediately prior to cognitive behavioral therapy ['ActiveCBT']) to treat depression.

Specific aims are to 1) demonstrate the effects of exercise priming on mechanisms associated with therapy success (i.e., working alliance, behavioral activation) and 2) determine the efficacy of exercise priming for treatment of depression and strength of relationship with engagement of target CBT mechanisms.

The primary outcomes of this trial are participant-rated working alliance and change in behavioral activation each averaged across all eight sessions. Secondary outcomes include post-intervention depressive scores (Hamilton Depression Rating Scale).

For safety, suicide severity will be evaluated using the Columbia-Suicide Severity Rating Scale.

Being tested
Rest, Aerobic Activity
Keywords
cognitive behavioral therapy, CBT
Medical subject headings
Depressive Disorder, Major

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • RestBehavioural

    30 minutes of rest while watching a nature documentary before cognitive behavioral therapy

  • Aerobic ActivityBehavioural

    30 minutes of aerobic activity before cognitive behavioral therapy, while watching the same nature documentary the CalmCBT group watches.

Study groups in NCT07221929
Study groupRoleWhat they receive
CalmCBTExperimentalIn this arm, participants would complete 30 minutes of rest while watching a nature documentary before cognitive behavioral therapy
Receives: Behavioral: Rest
ActiveCBTExperimentalIn this arm, participants would complete 30 minutes of aerobic activity before cognitive behavioral therapy, while watching the same nature documentary the CalmCBT group watches.
Receives: Behavioral: Aerobic Activity

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Working Alliance Inventory (WAI) - Bond subscale

    The WAI-Bond subscale scores 4 items, with scores ranging from 4-28. Higher scores are stronger perceived patient-therapist bond: how the participant experiences feelings of bond (i.e., feelings of mutual trust, acceptance, and connection) with their therapist.. The Bond subscale is a primary outcome measure for this study and the total score will be analyzed as a secondary outcome.

    Measured: data collected at each CBT session (weeks 1-8)

  2. Behavioral Activation for Depression Scale (BADS)

    BADS is a 25-item survey, each item scored from 0 (not at all) to 6 (completely), with some items reverse scored. There are 4 sub-scales: Activation, Avoidance / Rumination, Work / School Impairment, Social Impairment. The total possible range of scores is from 0 to 150 where higher scores indicate higher behavioral activation (increased avoidance and impairment).

    Measured: data collected at baseline, each CBT session (weeks 1-8), post intervention visit (week 9), week 20, week 52

  3. GRID Hamilton Rating Scale for Depression (GRID-HAMD)

    The GRID-HAM-D is a 17-item clinician-completed questionnaire that will be used to rate depressive symptom severity. The questionnaire is designed for adults and is used to rate the intensity and frequency of depressive symptoms by probing mood, feelings of guilt, suicidal ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms. As recommended by the Depression Rating Scale Standardization Team, Clinical Interviewers will follow the Structured Interview Guide and use GRID scoring, in which dimensions of intensity and frequency of a symptom are rated independently for each item. Higher scores reflect greater symptom severity, categorized as Normal (0-7), Mild Depression (8-13), Moderate Depression (14-18), Severe Depression (19-22), and Very Severe Depression (greater than 23).

    Measured: baseline, post intervention visit (week 9), week 20, week 52

  4. Patient Health Questionnaire-9 (PHQ-9)

    The PHQ-9 is a 9-item questionnaire that asks the participant to consider the last 2 weeks and score each question from 0-3 for a total possible range of scores from 0-27 where higher scores indicate increase depression.

    Measured: data collected at baseline, each CBT session (weeks 1-8), post intervention visit (week 9), week 20, week 52

Secondary outcomes (19)
  1. Structured Clinical Interviews for DSM-5 Disorders (SCID)

    The SCID is a semi-structured interview for making diagnoses according to the diagnostic criteria published in the American Psychiatric Association's Diagnostic and Statistical Manual for Mental Disorders. Scoring on the SCID modules results in binary outcomes per each diagnostic module: either meeting criteria for a disorder or not meeting criteria for a disorder. As a secondary outcome measure, only the Major Depressive Disorder (MDD) modules of the SCID will be used. Rates of meeting MDD diagnostic criteria at baseline and post-therapy will be the primary time points used to compare remission rates between groups.

    Measured: baseline, post intervention visit (week 9), week 20, week 52

  2. Columbia Severity Suicide Rating (CSSRS)

    The C-SSRS will be used to assess and monitor suicide ideation and behavior. The severity of the ideation subscale is rated on a 5-point ordinal scale: 1 = wish to be dead, 2 = nonspecific active suicidal thoughts, 3 = suicidal thoughts with methods, 4 = suicidal intent, and 5 = suicidal intent with plan. Suicide behaviors are rated on a nominal scale that includes actual, aborted, and interrupted attempts; preparatory behavior; and non-suicidal, self-injurious behavior.

    Measured: data collected at baseline, each CBT session (weeks 1-8), post intervention visit (week 9), week 20, week 52

  3. Dimensional Anhedonia Rating Scale (DARS)

    The DARS is a self-report measure that assesses state anhedonia across multiple domains. DARS is a 17-item survey on state anhedonia divided into four domains: hobbies, food/drink, social activities, and sensory experiences. Participants must list two activities within each of these categories that they consider their favorite and then respond to questions regarding their interest in/enjoyment of those activities on a 5-point Likert scale from "Not at all" to "Very much." During pre/post-administration, participants will be asked to respond to how they are feeling "right now."

    Measured: Weeks 1-8 CBT sessions (repeated 3 times [before exercise/calm condition, immediately after exercise/calm condition, and after therapy]), final visit (week 9), 20-week follow up, 1-year follow up

  4. Visual Analogue Scale (VAS)

    An anhedonia Visual Analog Scale [VAS] with 0 indicating 'No pleasure at all' and 100 indicating 'Greatest pleasure imaginable' will be used to measure anhedonia. In past research by the PI, correlations between the DARS and VAS were 0.49-0.69 indicating a moderate-to-strong agreement between the measures. The VAS will be used to provide a supplementary assessment of anhedonia.

    Measured: Weeks 1-8 CBT sessions (repeated 3 times [before exercise/calm condition, immediately after exercise/calm condition, and after therapy]), final visit (week 9), 20-week follow up, 1-year follow up

  5. Serum Brain Derived Neurotrophic Factor (BDNF)

    Serum BDNF will be quantified from a standard blood draw. Blood samples collected during Visits 1, 4, and 8 will be allowed to clot for 30 minutes and then centrifuged for ten minutes at 5500 RPM and 4 ◦C. Following centrifugation, blood serum will be extracted with samples stored at -80 ◦C until BDNF analysis. Enzyme-linked immunosorbent assay (ELISA) kits will measure the concentration of total BDNF in the serum according to the manufacturer's instructions. Each blood sample will be run in duplicate and averaged.

    Measured: Weeks 1, 4, and 8 CBT sessions (before exercise/calm condition, immediately after exercise/calm condition, and after therapy)

  6. Objective physical activity data (activPAL accelerometer) reported in minutes

    Participants will place an activPAL on the midline of the thigh on either leg and wear the monitor during all waking hours, removing it only for water-based activities (e.g., swimming). For data to be valid, the monitor must have been worn for 20 hours on at least 4 days, including a minimum of 3 weekdays and 1 weekend day. Sleep time will be parsed out from each day's sitting/lying time automatically using PALanalysis. From these data, average minutes of sitting per day will be used to assess total sedentary time, minutes of stepping time with a cadence greater than or equal to 75 and less than 100 will be used to assess minutes of light-intensity physical activity and minutes of stepping time with a cadence greater than or equal to 100 will be used to assess minutes of moderate to vigorous physical activity (MVPA).

    Sedentary time, physical activity time and sleep time will all be recorded in minutes per day.

    Measured: Baseline, weeks 3 & 8 CBT sessions (monitors worn 1 week following each time point)

  7. Objective physical activity data (activPAL accelerometer) reported in number of steps per day

    Participants will place an activPAL on the midline of the thigh on either leg and wear the monitor during all waking hours, removing it only for water-based activities (e.g., swimming). For data to be valid, the monitor must have been worn for 20 hours on at least 4 days, including a minimum of 3 weekdays and 1 weekend day.

    Steps are recorded as cumulative number of steps per day as measured by the activPAL device.

    Measured: Baseline, weeks 3 & 8 CBT sessions (monitors worn 1 week following each time point)

  8. Self-reported physical activity measured by the International Physical Activity Questionnaire - Short Form (IPAQ-SF) reported in minutes

    The IPAQ is a physical activity questionnaire that inquires about average amounts of walking, moderate physical activity, vigorous physical activity, and sitting time per week. Walking and physical activity are reported in minutes per day of activity, sitting time is reported in hours per day.

    Measured: baseline, week 4, post intervention visit (week 9), week 20, week 52

  9. 36-item Short Form health survey (SF-36)

    The SF-36 assesses health-related quality of life. It consists of eight scaled scores (including vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health), which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The higher the score the less disability (i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability).

    Measured: baseline, week 4, post intervention visit (week 9), week 20, week 52

  10. Generalized Anxiety Disorder 7 questionnaire (GAD-7)

    Generalized Anxiety Disorder 7 (GAD-7) is a self-reported questionnaire for measuring generalized anxiety disorder. GAD-7 has seven items, which measure the severity of various signs of GAD according to reported response categories of: Not at all (0 points), Several days (1 point), More than half the days (2 points), and Nearly every day (3 points), with scores of 5, 10, and 15 as cut-off points for mild, moderate and severe anxiety, respectively.

    Measured: baseline, week 4, post intervention visit (week 9), week 20, week 52

  11. Automatic Thoughts Questionnaire

    The ATQ is a 30-item instrument that measures the frequency of automatic negative statements about the self. Each item is rated on the frequency of an occurrence from "not at all" to "all the time". Total scores are the sum of all 30 items, with higher totals indicating a higher level of automatic negative self-statements.

    Measured: baseline, weeks 1-8, post intervention visit (week 9), week 20, week 52

  12. Session Evaluation Questionnaire (SEQ)

    Session Evaluation Questionnaire (SEQ) will be used to evaluate session effectiveness. This includes responses to twenty-one items in a 7-point bipolar adjective format questionnaire to assess how the client feels about each CBT session. The questionnaire assesses session depth, smoothness, positivity, and arousal. An overall score of the average of the values across each subscale will be used in this study.

    Measured: Weeks 1-8 CBT sessions

  13. Average Lyssn-generated score

    Lyssn is an AI-powered assessment platform for recording and managing session files, and all clinical interviews and therapy sessions will be recorded on the Lyssn platform. Lyssn will process the audio files from therapy sessions to generate session-level data.

    Lyssn generates metrics related to therapy effectiveness and fidelity, with individual metric scores (e.g., empathy, collaboration) ranging from 0 to 5 with higher scores indicated greater levels of the metric.

    Measured: Weeks 1-8 CBT sessions

  14. The Lam Employment Absence and Productivity Scale (LEAPS)

    The LEAPS is a 10-item self-report scale that provides a measure of productivity in the workplace. Scores range from 0 to 28, with higher scores indicating higher impairment in work productivity.

    Measured: baseline, post intervention visit (week 9), week 20, week 52

  15. The Patient Global Impression of Change scale (PGIC)

    The Patient Global Impression of Change scale is a single, self-administered question asking respondents to rate how their condition has changed since a certain point in time. Participants respond to the prompt "Since the start of the study, my overall status is: [1] 'Very Much Improved', [2] 'Much Improved', [3] 'Minimally Improved', [4] 'No Change', [5] 'Minimally Worse', [6] 'Much Worse', or [7] 'Very Much Worse'.

    Measured: Weeks 9, 20, and 52

  16. REST-Q

    The REST-Q is a 9-item questionnaire assessing the extent to which the participants' last night of sleep was restful or restorative. Scores range from 0-36, with higher scores indicating more restful sleep.

    Measured: baseline, post intervention visit (week 9), week 20, week 52

  17. Emotion Regulation Questionnaire (ERQ)

    The ERQ is a 10-item scale measuring emotional regulation on a 7-point scale for each question (total range: 7-70). Higher scores indicate increased use of emotion regulation strategies.

    Measured: baseline, post intervention visit (week 9), week 20, week 52

  18. Rumination Reflection Questionnaire (RRQ)

    The RRQ is a 24-item questionnaire assessing levels of rumination. Each item is scored 1-5 (total scores ranging 24-120). Higher scores indicate higher levels of rumination.

    Measured: baseline, post intervention visit (week 9), week 20, week 52

  19. Working Alliance Inventory (WAI) - Total

    The WAI scores 12 items from 1-7 in 3 domains: Tasks (4-28), Goals (4-28), Bond (4-28). Total possible range of scores from 12-84. In all domains higher scores are stronger perceived working alliance. The Bond subscale is a primary outcome measure. The total score and the two other subscales, Tasks and Goals, will be analyzed as secondary outcomes.

    Measured: data collected at each CBT session (weeks 1-8)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Oct 2025
  2. Study start5 Jan 2026
  3. Primary completionDec 2029 (estimated)
  4. Study completionDec 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Care provider, Investigator, Outcomes assessor
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07221929
Sponsor's protocol ID
2025-1128
Other IDs
R33MH129407, EDUC/KINESIOLOGY, Protocol Version 12/19/25
Status last verified
Mar 2026
First submitted
23 Oct 2025
Last updated
4 Mar 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Questionnaire data will be shared with the NIMH Data Archives (NDA).

Publications

  • Meyer JD, Kelly SJE, Gidley JM, Lansing JE, Smith SL, Churchill SL, Thomas EBK, Goldberg SB, Abercrombie HC, Murray TA, Wade NG. Protocol for a randomized controlled trial: exercise-priming of CBT for depression (the CBT+ trial). Trials. 2024 Oct 7;25(1):663. doi: 10.1186/s13063-024-08495-x.

    PubMed 39375728

Questions about this trial

What is this clinical trial studying?

A study testing Rest and Aerobic Activity in people with Major Depressive Disorder, run by University of Wisconsin, Madison at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 4 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Madeleine Connolly, PhD ((608) 890-0154, mconnolly5@wisc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Working Alliance Inventory (WAI) - Bond subscale (time frame: data collected at each CBT session (weeks 1-8)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07221929, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in